PubRank
Search
About
Study of BMS-663513 in Patients With Advanced Cancer
Clinical Trial ID NCT00309023
PubWeight™ 12.59
‹?›
🔗 Visit the ClinicalTrials.gov page for NCT00309023
Top papers
Rank
Title
Journal
Year
PubWeight™
‹?›
1
Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion.
Blood
2009
1.81
2
Agonist antibodies to TNFR molecules that costimulate T and NK cells.
Clin Cancer Res
2013
1.33
3
A novel form of 4-1BBL has better immunomodulatory activity than an agonistic anti-4-1BB Ab without Ab-associated severe toxicity.
Vaccine
2009
1.09
4
Immune checkpoint inhibitors in clinical trials.
Chin J Cancer
2014
0.98
5
4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity.
Front Oncol
2015
0.97
6
Immunotherapy of melanoma with the immune costimulatory monoclonal antibodies targeting CD137.
Clin Pharmacol
2013
0.89
7
Immune checkpoint inhibitors: therapeutic advances in melanoma.
Ann Transl Med
2015
0.87
8
SA-4-1BBL as a novel adjuvant for the development of therapeutic cancer vaccines.
Expert Rev Vaccines
2014
0.85
9
Principles of antibody-mediated TNF receptor activation.
Cell Death Differ
2015
0.84
10
4-1BB agonism: adding the accelerator to cancer immunotherapy.
Cancer Immunol Immunother
2016
0.81
11
Targeting CD8+ T-cell tolerance for cancer immunotherapy.
Immunotherapy
2014
0.81
12
ProtEx technology for the generation of novel therapeutic cancer vaccines.
Exp Mol Pathol
2009
0.79
13
Anti-CD137 enhances anti-CD20 therapy of systemic B-cell lymphoma with altered immune homeostasis but negligible toxicity.
Oncoimmunology
2016
0.75
Next 100